EcoDrugPlus

Bruton Tyrosine Kinase

Ensembl ID : ENSLCAG00010001486
Gene Symbol: BTK
4 Cross references
204 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSLCAG00010014618
Gene Symbol: CCR9
4 Cross references
193 Possible Orthologues:

C-X-C Chemokine Receptor Type 4

Ensembl ID : ENSLCAG00010011228
Gene Symbol: LOC108886893
4 Cross references
201 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSLCAG00010028044
Gene Symbol: CXCR1
4 Cross references
275 Possible Orthologues:

C-Reactive Protein

Ensembl ID : ENSLCAG00010015004
Gene Symbol: LOC108889630
3 Cross references
354 Possible Orthologues:

C-Reactive Protein

Ensembl ID : ENSLCAG00010013088
Gene Symbol: LOC108892133
3 Cross references
415 Possible Orthologues:

C-Reactive Protein

Ensembl ID : ENSLCAG00010018026
Gene Symbol: LOC108890041
3 Cross references
358 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSLCAG00010000986
Gene Symbol: LOC108893910
4 Cross references
214 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSLCAG00010023188
Gene Symbol: LOC108893793
4 Cross references
165 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSLCAG00010025990
Gene Symbol: LOC108902999
4 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSLCAG00010021519
Gene Symbol: TOP1
4 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSLCAG00010010228
Gene Symbol: LOC108875718
4 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).